Delay in Cancer Diagnosis: NCDRC upholds compensation order against doctor for medical negligence

New Delhi: The National Consumer Disputes Redressal Commission (NCDRC) recently held an Andhra Pradesh-based doctor guilty of medical negligence for the delay in cancer diagnosis of a patient who was suffering from breast pain.

“…the continuous therapy and reluctance to even record the advice for further diagnostic investigations to find out the nature and prognosis of the lesions already noted in the Mammography Report would certainly suggest clear negligence on the part of the Petitioner as the Consulting Physician/ Family Doctor of the Complainant, since the lump originally seen at the earlier stage in the investigations had grown very rapidly till the surgery was performed four months later,” noted the Apex Consumer Court, upholding the Rs 6 lakh compensation slapped on the doctor by the District Commission.

The history of the case goes back to 2011 when the patient consulted the doctor as she was suffering from pain in her right breast. The doctor, after clinical examination, prescribed medicines and advised her to undergo a pathological test for diagnosis. Accordingly, the patient underwent a mammography test.

Meanwhile, despite the subsequent medication, the pain persisted and the doctor recommended surgery to remove the lump in the right breast. Consequently, on 11.05.2011, the patient underwent surgery for the removal of the lump and a piece of it was sent for biopsy to a Diagnostic Centre in Rajahmundry. 

Post-surgery, the patient followed the instructions for care given by the treating doctor. However, since there was still no relief from the pain, she sought further consultation at G.S.L Cancer Hospital, as per the treating doctor’s referral.

The biopsy report revealed infiltrative duct cell carcinoma, with the tumor deemed inoperable due to its growth. Subsequently, at NIMS Hospital, Hyderabad, her right breast was surgically removed. Allegedly, it was only post-surgery, upon consultation with doctors at NIMS Hospital and GSL Hospital, that the patient realized the alleged improper treatment by the treating doctor.

It was claimed by the petitioner that the issue of cancer was initially indicated in the report dated 27.01.2011 indicating negligence by the treating doctor. Subsequent treatments included weekly chemotherapy at NIMS Hospital and radiotherapy at GSL Cancer Hospital, Rajahmundry, resulting in side effects such as hair loss and loss of appetite, impacting her ability to care for her family.

Since the doctor did not agree to pay the damages, the patient approached the District Consumer Court and filed a complaint. While considering the matter, the District Commission in 2015 directed the doctor to pay the complainant Rs 5 lakh towards compensation, Rs 1 lakh towards mental agony and Rs 5,000 towards litigation costs.

The order of the District Commission was challenged before the State Commission, Andhra Pradesh, which upheld the order of the District Forum. Challenging this, the doctor approached the Apex Consumer Court.

Approaching the NCDRC, the counsel for the treating doctor claimed that the lower Fora erred in allowing the complaint without duly considering the impeccable track record of the treating doctor spanning four decades of medical practice. Further, it was contended that negligence was wrongly attributed to the treating doctor without considering the comprehensive evidence, including that of an Oncology Surgeon.

It was also claimed by the doctor’s counsel that due to the complainant’s young age and her relatively small size of lump according to the Mammogram and Ultrasound, diagnosing cancer was challenging. It was also submitted that the treatment provided by the treating doctor was 2.5 years before the complainant’s death, with the cause of death remaining undisclosed.

Apart from this, the doctor’s counsel also argued that the absence of an explanation for the 2-month gap between the Complainant’s discharge from the petitioner’s hospital and the subsequent surgery suggested a potential exacerbation of the disease during this period.

On the other hand, the counsel for the complainants argued that there was a delay in the correct diagnosis and administration of treatment by the treating doctor from 10.01.2011 to 26.05.2011. This delay adversely affected the outcome of the treatment, particularly considering the young age of the patient and the aggressive nature of the disease with poor diagnosis/biological factors.

The complainants also submitted evidence by an expert doctor, who emphasized the negative impact of the treatment delays. The counsel for the complainants submitted that the doctor’s admission during evidence undermined her own defence since she admitted to not recording suspicions about the mass in the medical records and the prescribed antibiotics and anti-inflammatory drugs initially, followed by iron tablets after blood investigations.

Therefore, it was argued that the failure to prescribe further diagnostic tests such as MRI, CT Scan, and FNAC, coupled with the absence of estrogen testing before surgery, were instances of negligence. It was contended that the absence of a biopsy and FNAC recommendation, along with reliance solely on a normal mammogram, was deemed inadequate for ruling out breast cancer.

While considering the matter, the top consumer court took note of the orders passed by both the District and State Commission and observed,

“Both of them have come to the conclusion that there was negligence/ deficiency in service on the part of the Petitioner/Opposite Party who did not advise appropriate investigations in time, which resulted in a fast progression in the disease of Breast Cancer for which the deceased Complainant had actually been suffering. In fact, the Ld. State Commission in its Order has noted that when the pain and affliction being suffered by the deceased Complainant persisted in spite of the conservative treatment prescribed by the Petitioner, no investigations were advised on no less than 5 different occasions between 10.1.2011 to 24.3.2011.”

“The defence raised in her Written Version that she had orally advised such investigations, but the Complainant herself was reluctant to undergo the same, cannot be regarded as a credible excuse for not writing the advice or not recording the oral advise and reluctance of the Complainant as claimed in the relevant Prescription slips. Furthermore, even in the Mammography and SonoMammography Report dated 27.1.2011 (Annexure-P1), it was noted that the “…Right Breast shows two small irregularly oval hypoechoic lesions….., multiple internal echoes….” and the final impression was “SMALL EVOLVING ABSCESSES- RIGHT BREAST”. About 4 months later on 26.5.2011 ultimately the Biopsy Report of the Right Breast Lump established Cancer,” noted the Apex consumer court.

Holding that the treating doctor was negligence, the NCDRC bench noted,

“In the given facts and circumstances, the continuous therapy and reluctance to even record the advice for further diagnostic investigations to find out the nature and prognosis of the lesions already noted in the Mammography Report would certainly suggest clear negligence on the part of the Petitioner as the Consulting Physician/ Family Doctor of the Complainant, since the lump originally seen at the earlier stage in the investigations had grown very rapidly till the surgery was performed four months later.”

Clarifying that NCDRC cannot go into re-appreciation of evidence, the consumer court upheld the order passed by the District and State Commission. “Consequently, this Commission finds no grounds whatsoever to interfere with the concurrent decisions of both the Ld. Fora below. The Revision Petition is therefore dismissed. Parties to bear their own costs,” it noted.

To view the order, click on the link below:

https://medicaldialogues.in/pdf_upload/ncdrc-rs-6-lakh-compensation–236102.pdf

Also Read: NCDRC Grants Rs 9.77 Crore Relief to Surgeons, says MBBS doctors can perform Hair Transplant Procedures:

Powered by WPeMatico

Subcutaneous infusion of levodopa-carbidopa beneficial for Parkinson’s disease

Subcutaneous infusion of ND0612 (a levodopa-carbidopa solution) increases on time without troublesome dyskinesia among patients with Parkinson disease, according to a study published online March 15 in The Lancet Neurology.

Powered by WPeMatico

ACC: Ticagrelor monotherapy cuts bleeding risk in acute coronary syndrome

Treatment with ticagrelor alone results in a lower rate of clinically relevant bleeding compared with ticagrelor and aspirin among patients with an acute coronary syndrome who had percutaneous coronary intervention and remained event-free for one month on dual antiplatelet therapy, according to a study published online April 7 in The Lancet to coincide with the annual meeting of the American College of Cardiology, held from April 6 to 8 in Atlanta.

Powered by WPeMatico

Some breast cancer patients can retain lymph nodes, avoiding lymphedema

Removal of armpit lymph nodes can leave many breast cancer patients with lingering lymphedema, a painful and unsightly swelling of the arm.

Powered by WPeMatico

Brain scans of Philly jazz musicians reveal secrets to reaching creative flow

Flow, or being “in the zone,” is a state of amped-up creativity, enhanced productivity and blissful consciousness that, some psychologists believe, is also the secret to happiness. It’s considered the brain’s fast track to success in business, the arts or any other field.

Powered by WPeMatico

AACR: At-home HPV testing boosts cervical cancer screening participation

Mailed at-home self-sampling for human papillomavirus (HPV) testing increases cervical cancer screening participation in underscreened populations by almost threefold, according to a study presented at the annual meeting of the American Association for Cancer Research, held from April 5 to 10 in San Diego.

Powered by WPeMatico

Lack of Basic Infrastructure: Doctor flags Plight of AIIMS Madurai Medicos, says Institute’s reputation doesn’t match reality

New Delhi: In a shocking post, a Delhi-based doctor and Health Activist has highlighted the plights of medical students at All India Institute of Medical Sciences (AIIMS), Madurai as he claimed that the institute lacks even the basic infrastructure required to run a medical college.

Unveiling the ‘real’ condition of the institute, Dr. Dhruv Chauhan, a Med-Influencer and also the National Committee Co-ordinator of the Indian Medical Association Junior Doctors’ Network (IMA-JDN) has expressed his disappointment over the fact that the reputation of AIIMS, a premier medical institute, does not match the current scenario of AIIMS Madurai.

Taking to X (formerly Twitter), Dr. Chauhan highlighted the condition of the institute and claimed that the students are pleading with the authorities to shift them to other medical colleges. According to Dr. Chauhan, this situation is a result of opening so many medical colleges without any basic facilities.

As per the X post, there are no patients in wards at the institute for clinical examination and there is a prohibition in visiting the OPD and OT as well. He also claimed that the institute lacks proper facilities to accommodate the medical students and as a result, 5 students are staying in a single room.

He also alleged that the libraries at the institute are so poor that there are no books for anyone except the 1st year medical students. In another post, he shared a picture of a library showing only one of the two almirahs in the picture filled with books.

Sharing the picture, Dr Chauhan wrote, “AIIMS madurai Library , even local street libraries have more books than this , here they don’t have anything for 2nd and 3rd year MBBS students !”

Also Read: AIIMS Madurai construction likely to start in December 2023: Health Minister Ma Subramanian

“AIIMS” the institution name sounds a big thing no ? But not anymore !” he mentioned in a post. On the one hand, he highlighted the problems faced by the medicos due to lack of facilities, and on the other, he mentioned in the post, “On asking the administration the reply is “who asked you to join AIIMS Madurai” ? This is the result of opening so many Medical colleges without any basic facilities !”

Responding to the post, some of the users questioned how there are students at the institute when AIIMS Madurai has not been even constructed yet. Explaining the situation, the doctor mentioned in another X post, “The answer is AIIMS Madurai has a temporary campus where 3 MBBS batches reside And their students go to GMC ramanathpuram college where they are studying in the “name of Aiims Madurai” and they don’t get any facilities because the GMC students are already there and occupancy is not sufficient .”

“So the question is it has been 4 years and in the name of admission of Aiims Madurai people have to study in state college while the tag is still of Aiims ! Isn’t it strange in itself ? Does that mean Aiims = GMC ?” he questioned, adding “Not just study they will graduate in the name of Aiims Madurai while their college will remain GMC ramanathpuram.”

Speaking to Medical Dialogues in this regard, Dr. Dhruv Chauhan informed that many students had approached him raising the issue. “AIIMS Madurai has 3 batches and are running in the name of temporary campus with their college and hospital as GMC Ramanathapuram. The AIIMS Madurai batches will pass even before seeing the building which is not even constructed yet and running in GMC which itself doesn’t provide them sufficient facilities,” he said.

Medical Dialogues team had earlier reported that the institute was finally expected to be completed by 2028, with its construction to begin by December 2023 and the tender for the construction was also floated.

However, earlier this year a Public Interest Litigation (PIL) was filed before the Madras High Court highlighting the prolonged delay in the construction of AIIMS Madurai and taking note of the issue, the HC bench of Justices D. Krishnakumar and Vijayakumar had earlier issued notices into the matter.

Also Read: Madras HC issues notice to Centre on PIL to expedite construction of AIIMS Madurai

Powered by WPeMatico

Sakra World Hospital completes 100 Robotic GI Surgeries

Bengaluru: Sakra World Hospital, a pioneering healthcare facility in India funded entirely by foreign direct investment (FDI), has successfully completed 100 robotic gastrointestinal (GI) surgeries.

In the medical field, robotic-assisted surgical procedures are steadily on the rise. The increasing acceptance of robotic surgeries can be attributed to their accuracy, minimally invasive techniques, and capacity to improve surgical outcomes. With a group of skilled surgeons and cutting-edge facilities, Sakra World Hospital has become a pioneer in leveraging this technology to help patients suffering from gastrointestinal surgical issues.

Also Read:Bengaluru Orthopaedician Dr Banarji B H gets patent for Arthroscopic Carpal Tunnel Release

Robotic-assisted surgery enables the performance of intricate procedures across a wide spectrum, including colorectal cancers, benign and malignant conditions of liver, biliary system, and pancreas, apart from complex hernia repairs, gallbladder removals, and abdominal wall reconstruction. With a focus on less trauma and greater precision in these surgical interventions, Sakra tremendously benefits patients specializing in upper gastrointestinal surgeries, such as giant hiatal hernias, gastroesophageal reflux disease (GERD), Heller’s myotomy, and even uncommon conditions like median arcuate ligament syndrome.

“We take immense pride in reaching a significant milestone in robotic GI surgeries, underscoring the skill and commitment of our proficient surgical team,” lauded Lovekesh Phasu, Chief Operating Officer, Sakra World Hospital, Bengaluru, adding, “At Sakra, we’re committed to setting high standards and achieving them, to benefit our patients and provide quality healthcare for all.”

The application of robot-assisted technologies has greatly improved surgical capabilities in GI surgeries. These systems are operated directly by surgeons, in contrast to autonomous systems, which enable careful dissection around target organs. Although laparoscopic surgery provides benefits such as accurate dissection under high-resolution imaging and minimally invasive procedures, it has limitations due to the limited dexterity of the instruments. These limitations are overcome by the existing robotic system’s articulated instruments, vibration filtering, and motion scaling functions. These capabilities allow surgeons to perform more versatile surgeries than they could with the standard laparoscopic equipment.

Moreover, the robotic system’s instruments with wrist-like movements and dexterity assures delicate tissue handling and precision surgery with minimal bleeding. This capability, coupled with three-dimensional magnified, enhanced imaging, provides a platform wherein complex procedures in critical places and organs can be safely performed. Through these innovations, robotics surgery in the gastrointestinal realm continues to push boundaries, enhancing surgical precision and expanding treatment options for patients.

Robotic GI surgery has emerged as a reassuring alternative to traditional methods, dispelling common fears. The robotic system not only provides surgeons with better visualization and precision, but the patient also benefits from smaller incisions, less blood loss, quicker recovery, and reduced post-operative pain.

“The completion of 100 robotic GI surgeries at Sakra World Hospital not only marks a numerical achievement, but also serves as evidence of the hospital’s steadfast dedication to delivering top-notch care to its patients,” remarked Dr Sadiq Saleem Sikora, Director of Gastrointestinal Surgery and Liver Transplantation at Sakra World Hospital, Bengaluru.

Powered by WPeMatico

From this year, MUHS to conduct online Evaluation of Answer Sheets

Maharashtra- After last year’s successful trials on the online evaluation of answer sheets, Maharashtra University of Health Sciences (MUHS) has decided to conduct an online evaluation of answer sheets instead of a manual evaluation for all courses from this academic year.

Following the fewer errors and declaring the results on time last year, the plan has been now officially firmed up as it will significantly help in reducing the errors and expediting the declaration of results within two weeks.

This online evaluation of answer sheets will significantly help MUHS to declare the results within two weeks as compared to the standard 1.5 months. To start this process, a digital evaluation centre is being set up in each medical college with an examination coordinator who will scan the answer sheets.

According to HT Media News report, the MUHS official said “These centres are under CCTV surveillance. Once the professor starts assessing answer sheets after logging in, they will get an OTP on their phone that will record all steps involved with the assessments”.

Thousands of exams are conducted every year. The benefit of having an online assessment is be the results won’t get delayed. Also, the software sends alerts if the assessor has missed checking an answer” the official further added.

MUHS officials said the new pattern of evaluation of answer sheets is on the lines of Rajiv Gandhi University of Health Sciences in Karnataka. They had visited the university before conducting the pilot run.

The Pilot project was implemented during the Bachelor of Dental Surgery (BDS), MBBS and PG examinations between December 2022 and June this year. During this pilot project, MUHS evaluated more than 28,300 answer sheets and the results were declared in two days.

On this, the vice-chancellor Lt Gen Dr Madhuri Kanitkar (retd) also said “Last year, on a pilot basis, we conducted an online assessment of certain answer sheets and it was observed that it was a more viable option. We have now decided to implement online assessment in all the courses from this academic year“.

Powered by WPeMatico

Arvinas, Novartis collaborate for development, commercialization of ARV-766 for prostate cancer

New Haven: Arvinas, Inc., a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, has announced it has entered into an exclusive strategic license agreement with Novartis for the worldwide development and commercialization of ARV-766, Arvinas’ second generation PROTAC androgen receptor (AR) degrader for patients with prostate cancer. The transaction also includes an asset purchase agreement for the sale of Arvinas’ preclinical AR-V7 program to Novartis.

“We are thrilled to partner with an organization that shares our dedication to delivering transformative medicines to patients with significant unmet need,” said John Houston, Ph.D., Chairperson, President and Chief Executive Officer of Arvinas. “We believe the expertise and scale of Novartis will broaden the development of ARV-766 and its potential to be a first- and best-in-class treatment for patients with prostate cancer. This strategic transaction also further validates our innovative PROTAC protein degrader platform and its potential to deliver new treatments.”

Under the terms of the transaction agreements, Novartis will be responsible for worldwide clinical development and commercialization of ARV-766 and will have all research, development, manufacturing, and commercialization rights with respect to the preclinical AR-V7 program. Arvinas will receive an upfront payment in the aggregate amount of $150.0 million. Under the License Agreement, Arvinas is eligible to receive additional development, regulatory, and commercial milestones of up to $1.01 billion, as well as tiered royalties for ARV-766.

Closing of the transaction is subject to the parties’ receipt of any necessary consents or approvals, including the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976. Goldman Sachs & Co. LLC is acting as the exclusive financial advisor to Arvinas.

ARV-766 is an investigational orally bioavailable PROTAC protein degrader designed to selectively target and degrade the androgen receptor (AR). Preclinically, ARV-766 has demonstrated activity in models of wild type androgen receptor tumors in addition to tumors with AR mutations or amplification, both common potential mechanisms of resistance to currently available AR-targeted therapies.

Arvinas is a clinical-stage biotechnology company. Arvinas uses its proprietary PROTAC Discovery Engine platform to engineer proteolysis targeting chimeras, or PROTAC targeted protein degraders, that are designed to harness the body’s own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. In addition to its preclinical pipeline of PROTAC protein degraders against validated and “undruggable” targets, the company has four investigational clinical-stage programs: vepdegestrant (ARV-471) for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer; ARV-766 and bavdegalutamide for the treatment of patients with metastatic castration-resistant prostate cancer; and ARV-102 for the treatment of patients with neurodegenerative disorders.

Read also: Novartis tender offer for MorphoSys AG commences

Powered by WPeMatico